Letter: Comparing first-line infliximab and vedolizumab for ulcerative colitis-it depends on how you use the drug. Authors' reply

Aliment Pharmacol Ther. 2024 Jan;59(1):142-143. doi: 10.1111/apt.17796. Epub 2023 Nov 4.

Authors

Bernd Bokemeyer^{1

2

3}, Sandra Plachta-Danielzik³

Affiliations

¹ Interdisciplinary Crohn Colitis Centre Minden, Minden, Germany.
² Department of Medicine I, UKSH, Kiel University, Kiel, Germany.
³ Competence Network IBD, Kiel, Germany.

PMID: 37924219
DOI: 10.1111/apt.17796

No abstract available

Publication types

Letter

MeSH terms

Antibodies, Monoclonal / therapeutic use
Antibodies, Monoclonal, Humanized / therapeutic use
Colitis, Ulcerative* / diagnosis
Colitis, Ulcerative* / drug therapy
Humans
Infliximab / therapeutic use

Substances

Infliximab
vedolizumab
Antibodies, Monoclonal, Humanized
Antibodies, Monoclonal